Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy

NCT01954745 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01954745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01954745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
June 30, 2016
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, cholangiocarcinoma of the extrahepatic bile duct, intrahepatic cholangiocarcinoma